Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Segeja, Method D ^a   Mmbando, Bruno P ^a   Seth, Misago D ^a   Lusingu, John P ^a   Lemnge, Martha M ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADOLESCENT; AGE DISTRIBUTION; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; BLOOD SMEAR; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MALARIA; MALARIA FALCIPARUM; PARASITE PREVALENCE; POPULATION DENSITY; SCHOOL CHILD; TANZANIA; ADULT; AGE; ANIMAL; BLOOD; EPIDEMIOLOGY; IMMUNOLOGY; NEWBORN; PARASITEMIA; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; AGE FACTORS; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; INFANT, NEWBORN; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SEROEPIDEMIOLOGIC STUDIES; STATISTICS AS TOPIC; TANZANIA; YOUNG ADULT;

EID: 77950444041     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-55     Document Type: Article

References (32)

1. Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 2001, 64:1-11.
2. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004, 72:247-252. 10.1128/IAI.72.1.247-252.2004, 343946, 14688102.
3. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, et al. Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 1992, 14:321-337. 10.1111/j.1365-3024.1992.tb00471.x, 1625908.
4. Druilhe P, Perignon JL. Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol Lett 1994, 41:115-120. 10.1016/0165-2478(94)90118-X, 8002025.
5. Perignon JL, Druilhe P. Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz 1994, 89(Suppl 2):51-53.
6. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420. 10.1016/S0140-6736(04)17223-1, 15488216.
7. Ballou WR, Arevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, et al. Update on the clinical development of candidate malaria vaccines. Am J Trop Med Hyg 2004, 71:239-247.
8. Bejon P, Peshu N, Gilbert SC, Lowe BS, Molyneux CS, Forsdyke J, et al. Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya. Clin Infect Dis 2006, 42:1102-1110. 10.1086/501459, 16575727.
9. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994, 84:1594-1602.
10. Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, et al. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 2004, 59:363-372. 10.1111/j.0300-9475.2004.01409.x, 15049780.
11. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, Chantavanich P, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991, 45:297-308.
12. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, Druilhe PL. A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 2007, 178:3099-3106.
13. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995, 182:409-418. 10.1084/jem.182.2.409, 2192140, 7629503.
14. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, Marsh K. Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol 2002, 24:77-82. 10.1046/j.0141-9838.2001.00440.x, 11874562.
15. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 2007, 25:2723-2732. 10.1016/j.vaccine.2006.05.090, 17280744.
16. Lusingu JPA, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malaria J 2009, 8:163.
17. Bodker R, Akida J, Shayo D, Kisinza W, Msangeni HA, Pedersen EM, et al. Relationship between altitude and intensity of malaria transmission in the Usambara Mountains, Tanzania. J Med Entomol 2003, 40:706-717. 10.1603/0022-2585-40.5.706, 14596287.
18. Maxwell CA, Chambo W, Mwaimu M, Magogo F, Carneiro IA, Curtis CF. Variation of malaria transmission and morbidity with altitude in Tanzania and with introduction of alphacypermethrin treated nets. Malar J 2003, 2:28. 10.1186/1475-2875-2-28, 239954, 14585106.
19. Mmbando BP, Segeja MD, Msangeni HA, Sembuche SH, Ishengoma DS, Seth MD, Francis F, Rutta AS, Kamugisha ML, Lemnge MM. Epidemiology of malaria in an area prepared for clinical trials in Korogwe, north-eastern Tanzania. Malaria J 2009, 8:165.
20. Lusingu JP, Vestergaard LS, Mmbando BP, Drakeley CJ, Jones C, Akida J, et al. Malaria morbidity and immunity among residents of villages with different Plasmodium falciparum transmission intensity in North-Eastern Tanzania. Malar J 2004, 3:26. 10.1186/1475-2875-3-26, 514496, 15282030.
21. Mnzava AE, Kilama WL. Observations on the distribution of the Anopheles gambiae complex in Tanzania. Acta Trop 1986, 43:277-282.
22. Reyburn H, Mbatia R, Drakeley C, Bruce J, Carneiro I, Olomi R, Cox J, Nkya WM, Lemnge M, Greenwood BM, Riley EM. Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA 2005, 293(12):1461-1470. 10.1001/jama.293.12.1461, 15784869.
23. Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Thiesen M, Corradin G, Cousens S, Ouattara AS, IIboudo-Sanogo E, Sirima BS. Do antibody responses to malaria vaccine candidates influenced by the levels of malaria transmission protect from malaria?. Tropical Medicine and International Health 2008, 13(2):229-237.
24. Lusingu JPA, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malaria J 2009, 8:163.
25. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 2008, 76:759-766. 10.1128/IAI.01147-07, 2223475, 18070896.
26. Soe S, Khin SA, Htay A, Nay W, Tin A, Than S, et al. Premunition against Plasmodium falciparum in a malaria hyperendemic village in Myanmar. Trans R Soc Trop Med Hyg 2001, 95:81-84. 10.1016/S0035-9203(01)90342-6, 11280074.
27. Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, Milligan P, et al. Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malar J 2008, 7:142. 10.1186/1475-2875-7-142, 2529305, 18664257.
28. Drakeley CJ, Corran PH, Coleman PG, et al. Estimating medium and long term trends in malaria transmission by using serological markers of malaria exposure. Proceedings of the National Academy of Sciences USA 102:5108-5113.
29. Tongren JE, Drakeley CJ, McDonald SL, Reyburn HG, Manjurano A, Nkya WM, Lemnge MM, Gowda CD, Todd JE, Corran PH, Riley EM. Target antigen, age and duration of antigen exposure independently regulate Immunoglobulin G subclass switching in malaria. Infection Immun 2006, 74:257-264.
30. Pleass RJ, Woof JM. Fc receptors and immunity to parasites. Trends Parasitol 2001, 17:545-551. 10.1016/S1471-4922(01)02086-4, 11872400.
31. Askjaer N, Maxwell C, Chambo W, et al. Insecticide treated bednets reduce plasma antibody levels and limit the repertoire of antibodies to Plasmodium falciparum variant surface antigens. Clinical and disgnostic Laboratory Immunology 2001, 8:1289-1291.
32. Nebie I, Cuzin-Ouattara N, Diallo DA, et al. Humoral responses to defined malaria antigens in children living since birth under insecticide treated curtains in Burkina Faso. Acta Tropics 2003, 88:17-25.